ArticleThoracic cancer2026
Predictive Value of Circulating Tumor Cells in Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer.
Article in Thoracic cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe incorporation of immune checkpoint blockade into preoperative regimens has significantly advanced the clinical management of locally advanced non-small cell lung cancer (NSCLC). Standard imaging modalities frequently fall short in assessing actual pathological regression. Our research sought to evaluate circulating tumor cells (CTCs) as an adjunct predictive tool, while uncovering the transcriptomic shifts within the tumor microenvironment that facilitate cellular shedding.
methodsA prospective cohort of 39 patients with NSCLC received neoadjuvant programmed cell death protein 1 (PD-1) inhibitors combined with platinum-doublet chemotherapy. Preoperative radiographic evaluations using RECIST 1.1 were cross-referenced with final pathological outcomes. Peripheral blood CTCs were enriched and phenotypically characterized via multiparametric immunofluorescence (CK, PD-L1). Bulk RNA-sequencing of residual tissue specimens was performed to identify gene signatures associated with CTC dissemination.
resultsThe cohort achieved a major pathologic response (MPR) rate of 38.5%, including a pathological complete response (pCR) rate of 23.1%. Preoperative cytokeratin-positive (CK+) CTC burden emerged as a potential independent predictor of pathological non-response (AUC = 0.757), outperforming total CTCs and PD-L1+ CTCs. Crucially, integrating CK+ CTC counts with standard radiographic imaging improved predictive accuracy for pathological outcomes (AUC = 0.79) compared to imaging alone (AUC = 0.54, p = 0.022). Transcriptomic profiling of the residual tumor microenvironment suggested that CTC dissemination may be associated with enhanced proliferative activity, severe local hypoxia and a broad immunological suppression within local microenvironments.
conclusionsPreoperative CTC monitoring may serve as a promising complementary biomarker to conventional radiographic imaging, with the potential to help resolve predictive ambiguities in neoadjuvant chemoimmunotherapy for NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.